MiNK Therapeutics Joined ARPA-H Room-Temperature Program
The biotech firm will help develop new storage methods to eliminate the need for cryogenic cold-chain logistics.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Should federal research prioritize logistics to make advanced medical therapies easier to distribute and store?
MiNK Therapeutics has joined the Advanced Research Projects Agency for Health (ARPA-H) BoSS program to pioneer cell therapy storage at room temperature. The project aims to transition medical logistics away from extreme cryogenic requirements.
Why it matters
The initiative seeks to reduce reliance on complex cold-chain infrastructure to broaden patient access to advanced cell-based medicines. Eliminating extreme temperature constraints could fundamentally simplify the distribution of life-saving therapies.
The BoSS program targets a shift from -196°C cryogenic storage to 21°C room-temperature storage for biologics. The project utilizes artificial intelligence to refine freeze-assisted droplet drying and hydrogel composition.
The players
MiNK Therapeutics
A clinical-stage biopharmaceutical company headquartered in New York that focuses on the development of allogeneic invariant natural killer cell therapies.
ARPA-H
The Advanced Research Projects Agency for Health is a federal agency within the U.S. Department of Health and Human Services that funds high-impact medical research.
Charles Stark Draper Laboratory
A research and development organization that is currently leading the Reversible Ambient Biostabilization team for the ARPA-H project.
The details
The research team is leveraging artificial intelligence-assisted design to optimize cell formulation and recovery media. By employing freeze-assisted droplet drying, researchers hope to create a stable, transportable product.
Timeline
MiNK Therapeutics announced its selection for the BoSS program on September 30, 2026.
The ARPA-H BoSS program is scheduled to operate over a four-year period.
The Tech Race
This development reflects the broader industry push to overcome the logistical bottlenecks inherent in current cell-based medicine. By replacing legacy cryogenic systems with ambient storage, firms are competing to define the future standard for medical distribution.
If successful, this technology could significantly lower the cost and increase the availability of specialized cell therapies for patients. It aims to reduce the logistical hurdles that currently limit where and how these advanced treatments can be administered.
The takeaway
The transition to ambient storage marks a significant potential turning point for the feasibility of mass-market cell therapy deployment. Patients and providers should monitor this progress as it may eventually change the storage requirements for critical medical supplies.
Further reading
Learn more about the latest innovations in Biotech to see how research is changing the industry landscape.
More information
View full details regarding the research initiative on the ARPA-H BoSS program official information page.
Live Poll
Should federal research prioritize logistics to make advanced medical therapies easier to distribute and store?
